Non Small Cell Lung Cancer (NSCLC)

Stage I-III: Unresectable

Treated w/SBRT +/- adjuvant chemo

LUN0115
Adjuvant Durvalumab for Early Stage NSCLC Patients with cDNA Minimal Residual Disease
PI: Neal Stanford

LUN0114
Personalized Escalation of Consolidation Treatment After ChemoRT & Immunotherapy in Stage IIB/III NSCLC
PI: Neal Stanford

LUN0118
Phase III Atezolizumab & Tiralagumab vsDurvalumab in Stage III NSCLC w/o ProgressionAfter Chemoradiation
PI: Wakelee Pending

Stage I-IV

VAR0203
Performance and Safety of Biology-Guided Radiotherapy using the RefleXion Medical Radiotherapy System
PI: Chang Stanford